Nectar Lifesciences Completes Slump Sale of API and Formulations Business; Shares Slip 3%

MT Newswires Live

2025/11/12

Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has completed the slump sale of its active pharmaceutical ingredients (API) and formulations business to Ceph Lifesciences, effective Nov. 10, according to a Tuesday filing.

Shares of the company were down over 3% at market close on Wednesday.

The transfer was executed as per the terms of the Business Transfer Agreement and Asset Purchase Agreement, both signed on July 7, and all completion deliverables under the agreements have been fulfilled, the company said in the filing.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582322068"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582322068\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582322068?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582322068","market":"sh","top_or_hot":-1,"title":"Nectar Lifesciences Completes Slump Sale of API and Formulations Business; Shares Slip 3%","media":"MT Newswires Live","content":"<html><body><p> Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has completed the slump sale of its active pharmaceutical ingredients (API) and formulations business to Ceph Lifesciences, effective Nov. 10, according to a Tuesday filing.</p><p>Shares of the company were down over 3% at market close on Wednesday.</p><p>The transfer was executed as per the terms of the Business Transfer Agreement and Asset Purchase Agreement, both signed on July 7, and all completion deliverables under the agreements have been fulfilled, the company said in the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nectar Lifesciences Completes Slump Sale of API and Formulations Business; Shares Slip 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNectar Lifesciences Completes Slump Sale of API and Formulations Business; Shares Slip 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-12 18:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has completed the slump sale of its active pharmaceutical ingredients (API) and formulations business to Ceph Lifesciences, effective Nov. 10, according to a Tuesday filing.</p><p>Shares of the company were down over 3% at market close on Wednesday.</p><p>The transfer was executed as per the terms of the Business Transfer Agreement and Asset Purchase Agreement, both signed on July 7, and all completion deliverables under the agreements have been fulfilled, the company said in the filing.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇圖資本持倉","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2582322068","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582322068","pubTimestamp":1762943540,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nectar Lifesciences  has completed the slump sale of its active pharmaceutical ingredients  and formulations business to Ceph Lifesciences, effective Nov. 10, according to a Tuesday filing.Shares of the company were down over 3% at market close on Wednesday.The transfer was executed as per the terms of the Business Transfer Agreement and Asset Purchase Agreement, both signed on July 7, and all completion deliverables under the agreements have been fulfilled, the company said in the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK6520":"工商业服务概念","API.AU":"Australian Pharma Industries","BK7103":"保健护理产品经销商","BK6100":"保健护理服务","OTX.SI":"迈怡汇有限公司","API":"声网","BK4023":"应用软件","BK4535":"淡马锡持仓","BK4503":"景林资产持仓"},"translate_title":"Nectar Lifesciences完成API和配方业务的大幅销售；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"API":1,"API.AU":1,"OTX.SI":1.5},"content_text":"Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has completed the slump sale of its active pharmaceutical ingredients (API) and formulations business to Ceph Lifesciences, effective Nov. 10, according to a Tuesday filing.Shares of the company were down over 3% at market close on Wednesday.The transfer was executed as per the terms of the Business Transfer Agreement and Asset Purchase Agreement, both signed on July 7, and all completion deliverables under the agreements have been fulfilled, the company said in the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}